WuXi Biologics hits 1,000th molecule milestone with Earendil Labs trispecific antibody
- WuXi Biologics recorded its 1,000th molecule on its integrated CRDMO platform, a trispecific antibody for ophthalmic diseases.
- The partnership advanced multiple novel bispecific and multispecific antibodies, fusion proteins and ADCs from DNA to IND with timelines outperforming industry averages.
- Collaboration aims to de-risk development and compress timelines across autoimmune diseases, oncology and other serious conditions.
- Earendil Labs leverages AI for protein-therapeutics discovery while WuXi provides integrated development, manufacturing and execution capabilities.
Milestone
WuXi Biologics’ integrated CRDMO platform reached its 1,000th supported molecule, represented by a trispecific antibody developed with Earendil Labs targeting ophthalmic diseases.
Collaboration outcomes
The two companies worked together to advance multiple modalities — including bispecific and multispecific antibodies, fusion proteins and antibody–drug conjugates — from DNA to IND with timelines the partners say outperform industry averages. The collaboration is positioned to accelerate programs across autoimmune diseases, oncology and other serious conditions by de-risking development and compressing schedules.
Capabilities and next steps
Earendil Labs combines AI-driven protein design with a discovery engine focused on protein-based therapeutics; WuXi Biologics provides end-to-end CRDMO execution, quality systems and manufacturing scale. Both parties say they will deepen the partnership to move more programs toward the clinic and translate computational innovation into therapeutic candidates for patients.
Source: WuXi
